HEOR Strategy & Gap Analysis

Clinical outcomes, benefits, and features alone are not enough to sell your product.
Seeking to understand the potential impact of technologies in real-world clinical settings in order to select the treatment option with the best possible value, clinicians, facilities, patients and payers, each with their own interests, look to health economics and outcomes research (HEOR) to help guide decision making.
HEOR allows you to quantify the economic and clinical outcomes associated with your technology, providing healthcare decision makers with evidence-based arguments for purchasing your product.

HEOR can be conducted within, or concurrent with, studies designed to support regulatory approval to serve a dual market access purpose.
HEOR allows for flexibility in study design. Studies can be conducted prospectively or retrospectively.
There is not currently a standardized process for requesting or using HEOR data for reimbursement decisions in the US.

We can review existing study protocols with a focus on opportunities for inclusion of HEOR supportive data (e.g., inclusion of itemized medical resource utilization (MRU), itemized billing data, necessary follow-up data relevant to MRU and billing such as adverse events and rehospitalizations during and after the index procedure) and maximize your HEOR strategy.
Combining real-world data from a number of sources including disease, device and medication registries; patient reported outcomes; insurance claims; billing claims; electronic health records and more with primary data collection, our experts can demonstrate your technology’s value in terms of clinical and economic outcomes.
Performing a HEOR gap analysis of existing evidence, we can identify missing elements and develop strategic recommendations for success with regulatory bodies, clinicians, facilities, patients, payers and other decision-makers.